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Abstract
Background: Unilateral adult thalamic gliomas are rarely reported. In this study, the authors aimed to analyze the
clinical, radiological, and pathological features of adult primary unilateral thalamus gliomas (UTGs).
Methods: Clinical data of 33 UTGs in adults who underwent surgical treatment between 2005 and 2014 at the
Beijing Tiantan Hospital were collected and retrospectively studied. Follow-up evaluation was performed.
Results: This study included 21 males and 12 females with a mean age of 43.1 years. The most common symptoms
were headache (75.8 %, 25/33 patients) and motor deficits (42.4 %, 14/33 patients). Radiological results showed that
enhancement was common (90.9 %, 30/33 patients) and included cystic appearances in 9 cases (27.3 %). All patients
underwent maximal safe tumor resection. Gross total resection (GTR) was achieved in 19 cases, subtotal resection
(≥80 %) in 9 cases, and partial resection (<80 %) in 5 cases. Molecular pathology results were available in 15 cases. After
surgery, 25 patients received postoperative adjuvant therapy based on the remaining pathology. The median follow-up
period of all 33 patients with UTGs was 17 months (1 week~49 months). Twenty-four patients experienced tumor
recurrence. The 1-year and 2-year progression-free survival (PFS) rates were 49.0 and 10.2 %, respectively. The 1-year
and 2-year overall survival (OS) rates were 68.1 and 25.9 %, respectively. Survival analyses revealed that several
predictive factors were correlated with better prognosis, among which, GTR and tumor with cystic appearances were
significantly associated with a longer survival.
Conclusions: Adult UTGs displayed a wide spectrum of clinical features. GTR can be achieved in adult UTGs with
acceptable complications and conferred a better prognosis. Tumor with cystic appearance may indicate better
prognosis. More patients and longer follow-up periods are needed to further elucidate the biological features of
adult UTGs.
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Background
Thalamic glomas represent 1 to 5 % of brain tumors [1–7].
This disease has been investigated in several studies span-
ning several decades. However, many previous series have
combined both adult and pediatric populations, despite
a highly differential prognosis between the two groups
[8–16]. Moreover, several previous studies have assessed
both tumors arising in the basal ganglia and other di-
encephalic structures [6, 17–22] and bilateral thalamic
gliomas [10, 23–27], despite the varying characteristics of
these gliomas and their associated treatment plans.
Due to decades of improvement in imaging modalities
and surgical techniques, a clear preoperative anatomical
picture and a more aggressive surgical treatment of these
deeply seated lesions are now available. Several recent
studies have revealed a more acceptable prognosis among
pediatric thalamic glioma patients [15, 28, 29]. However, it
is uncertain whether a more radical surgical procedure
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would benefit adult patients, and the prognosis of this age
group remains unknown. In this series, we retrospectively
reviewed patients with primary unilateral thalamic glioma
who underwent surgical operation at our hospital over a
period of 9 years. The aims were to clarify the clinical,
radiological, and pathological features and the behavior
and response to treatment and to identify the prognostic
factors of this diverse group of tumors.
Methods
Patient characteristics and inclusion/exclusion criteria
Consecutive patients’ notes and imaging studies were
reviewed; all included patients underwent operation
between 2005 and 2014 at the Beijing Tiantan Hospital.
Informed consent was provided by all patients or their
family members under an Institutional Review Board-
approved protocol at the Beijing Tiantan Hospital of the
Capital Medical University.
Our current study used the following inclusion cri-
teria: (1) histological diagnosis of gliomas and (2) patient
age older than 18 years at the time of diagnosis while
gliomas originating from adjacent structures but second-
arily involving thalamus and primary bilateral thalamic
gliomas were excluded, but the contrallateral growth of
a unilateral tumor was included in the study.
Clinical data, including age at presentation, sex, duration
and type of symptoms, preoperative Karnofsky Perform-
ance Status (KPS), side, cystic appearance, maximal tumor
diameter, treatment received, and status at the end of the
follow-up period, were recorded. All patients underwent
neuraxis magnetic resonance imaging (MRI) prior to treat-
ment and during the follow-up period. All neuroimages
and histological specimens were interpreted by two senior
neuroradiologist and two neuropathologists, respectively.
The T2/FLAIR images were used for defining the tumor
diameter. And the enhancing lesion present was also con-
sidered together with the T2/FLAIR for defining tumor
diameter.
Treatment protocols
All included unilateral thalamus glioma (UTG) patients
underwent tumor resection surgery aimed at achieving
maximal safe tumor resection. The extent of tumor resec-
tion was determined on the basis of early postsurgical
imaging and/or the neurosurgical report. Gross total tumor
resection was defined as macroscopic total removal of the
tumor mass, subtotal tumor resection was defined as a
removal of ≥80 % of the tumor mass, and partial tumor
resection was defined as <80 % resection. Various surgical
approaches (the precentral interhemispheric transcallosal
interforniceal approach, frontal transcortical approach, and
parieto-occipital transventricular approach) were used.
Postoperative adjuvant therapy was administrated based on
the pathology diagnosis as well as the extent of tumor
resection. All patients received prophylactic antiepileptic
treatments postoperatively for 1 week.
Statistical analysis
Statistical analysis was performed retrospectively using the
SPSS statistical package 16.0 (SPSS Inc). Overall survival
(OS) and progression-free survival (PFS) were determined
using Kaplan-Meier analysis and a log-rank test. Events
were defined as tumor relapse or progression, occurrence
of a secondary malignancy, or death due to any cause. All
of the clinical data of the one perioperative death and the
other two lost cases (lost to follow-up after discharging
from the hospital) were excluded prior to prognostic
relevance analysis. All UTGs were defined according to
the following parameters: sex, age at diagnosis, symptom
lateral, cystic appearance of tumors, maximum tumor
diameter, preoperative KPS status, grading of tumors, pre-
operative ventriculo-peritoneal (V-P) shunt, postoperative
V-P shunt, and extent of tumor resection. The cutoff
points were set as the median number for both categorical
variables and continuous variables under consideration of
the clinical practice (Table 5).
The prognostic relevance regarding PFS or OS of all
remaining thalamic gliomas was compared to establish
subgroups of the parameters defined above. The survival
analysis was completed for the same subgroups using a
Cox regression analysis. To compare the correlations be-
tween different subgroups, we performed the two-sided
chi-square test to determine the significances for each par-
ameter. The significance level was set at P < 0.05.
Results
Clinical, radiological features of patients with UTGs
Using the selection criteria, we identified 33 patients with
UTGs. The clinical and histological characteristics of the
33 cases of UTGs in the present study are summarized in
Table 1. Magnetic resonance images were available in all
33 UTGs (Table 2). The symptom duration from onset to
hospital admission ranged from 1 week to 12 months; the
median duration was 2 months. Among the 33 patients,
25 patients had headaches; 14 had motor deficits; 10 had
hyperesthesia; 8 had blur vision; 7 had hypomnesia; 7 had
dysphasia; and 1 had facial palsy. The median preoperative
KPS was 60 (ranging from 40 to 80). The postoperative
KPS was not collected.
All patients received maximal safe tumor resection
under the guidance of intraoperative ultrasound monitor-
ing. No patient received preoperative chemotherapy and/
or radiotherapy. Most of the patients received postopera-
tive adjuvant therapy (Table 1). Three patients received
clinical follow-ups without further treatment. One of these
patients was a middle-aged man who refused to receive
and adjuvant therapy and died 3 months after gross total
resection of the tumor due to glioblastoma, the second
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patient was a young man who remains alive with no
progression of disease after receiving a gross total re-
section of his thalamic glioma with the diagnosis of
astrocytoma, and the third patient was a middle-aged
woman who refused to receive any adjuvant therapy
and died 3 months after partial resection of the tumor
due to glioblastoma.
Perioperative management of cerebral spinal fluid
problems
Ventriculomagely was identified in 27 of the 33 cases
(81.8 %). Seven of the 27 cases (25.9 %) required an
emergent V-P shunt. All 7 V-P shunts were performed
in the ventricle contra-lateral to the lesion at 5 to 45 days
(median 12 days) prior to tumor resection. The other 20
Table 1 Clinical, radiological, and pathological features of 33 adult UTGs
No. Age (years) Sex Tumor location Side Diameter (cm) Resection Pathology Postop therapy Follow-up timea Status at the last follow-up
1 53 M Th +Mid Left 3.8 STR A Radio 25.5 Death with progression
2 20 F Th +Mid Right 4.1 PR GBM Radio 21 Death with progression
3 20 M Th + IC Right 4.2 STR AA Radio 17 Death with progression
4 33 M Th +Mid Right 4.1 GTR OA Radio 24 Death with progression
5 32 F Th Right 3.1 GTR AA Radio 24 Death with progression
6 47 F Th + BG Left 3.5 GTR GBM Radio 30 Death with progression
7 38 M TH +Mid Right 3.4 STR AA Radio 14 Death with progression
8 37 M Th Left 3.9 GTR A Radio 24 Death with progression
9 56 M Th Left 1.2 GTR A Radio 46 Alive without progression
10 42 M Th Right 3.2 GTR GBM Radio 49 Alive with progression
11 21 F Th Left 4.5 STR AA Radio 17 Death with progression
12 37 M Th + IC Left 3.5 GTR GBM Radio 14 Death with progression
13 29 M Th +Mid + IC Right 4.1 GTR A Radio 35 Death with progression
14 46 M Th + IC Left 5.3 GTR GBM – 1 Death without progression
15 33 M Th + IC Right 6.2 PR GBM – – Lost to follow-up
16 29 M Th + IC + PiR Right 4.5 GTR OAb Radio + chemo 25 Death with progression
17 49 F Th Right 3.5 GTR AA Radio 17 Death with progression
18 48 M Th Left 4.2 GTR AOb Radio + chemo 27 Death with progression
19 36 M Th + IC + CTh Right 3.2 PR AOAb Radio 20 Death without progression
20 24 M Th +Mid + IC Left 5.4 GTR Ab – 14 Alive without progression
21 52 F Th + CTh Right 2.5 STR AOb Radio + chemo 2 Death with progression
22 21 F Th +Mid Right 3.8 STR AOAb Radio + chemo 12 Alive without progression
23 45 F Th +Mid Right 4.2 GTR GBMb Radio + chemo 3 Death without progression
24 30 M Th Right 3.9 GTR GBMb Radio + chemo 11 Alive with progression
25 43 M Th Right 4.7 GTR AAb Radio + chemo 11 Alive without progression
26 63 F Th + IC Left 4.1 GTR OAb Chemo 16 Alive with progression
27 47 F Th + BG + IC Left 3.4 PR GBMb Radio + chemo 4 Alive without progression
28 45 F Th + IC Right 4.8 PR GBMb – 3 Death without progression
29 20 M Th +Mid Right 5.3 STR AAb Radio + chemo 21 Death with progression
30 53 F Th + CTh Left 5.1 GTR OA – – Lost to follow-up
31 31 M Th +Mid + IC Left 5.2 STR AOAb Radio 24 Death with progression
32 66 M Th +Mid + IC Right 4.5 GTR GSM Chemo 1 week Perioperative death
33 48 M Th +Mid Left 5.2 STR GBMb Radio + chemo 13 Death with progression
Th thalamus, Mid midbrain, IC internal capsule, BG basal ganglia, PiR pineal region, CTh contralateral thalamus, GTR gross total resection (≥90 % resection), STR
subtotal resection (≥80 but <90 %), PR partial resection (<80 %), A astrocytoma, AA anaplastic astrocytoma, AO anaplastic oligodendroglioma, AOA anaplastic
oligodendroastrocytoma, GBM glioblastoma, GSM gliosarcoma, OA oligoastrocytoma
aThe follow-up time take the month as the unit
bThe molecular pathologies were available
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patients with some degree of ventriculomegaly were not
treated, thereby leaving additional room to facilitate tumor
resection through a transventricular approach.
After tumor resection, 4 patients with UTG (12.1 %)
developed hydrocephalus and received V-P shunts in the
ventricle contra-lateral to the lesion at 10, 13, 30, or
45 days after tumor resection, respectively.
Surgical findings and outcomes of patients with UTGs
The surgical findings and outcomes are summarized in
Table 3. The choice of the surgical approaches was based
on the tumor location as well as the preferences of
surgeon. The frontal transcortical approach was taken to
remove tumors located in the anterior part of the unilat-
eral thalamus in 6 cases, the precentral interhemispheric
transcallosal interforniceal approach was taken to re-
move tumors located in the middle part of the unilateral
thalamus in 5 cases, and the parieto-occipital transven-
tricular approach was taken to remove tumors located in
the posterior part of the unilateral thalamus in 22 cases.
Of note, when the tumors are located in the posterior part
of the left thalamus, the language function area should be
cautiously protected. Perioperative death occurred in one
case after tumor resection due to postoperative malignant
brain edema.
After tumor resection, headaches were significantly re-
lieved or eliminated in 25 cases. Among the 14 patients
with preoperative motor deficits, 4 cases demonstrated ob-
vious improvement, 5 cases showed no significant changes,
and 5 cases exhibited postoperatively deterioration, includ-
ing the one death due to postoperative malignant brain
edema. In the 10 cases with preoperative hyperesthesia,
obvious improvement was observed in 2 cases; the other 8
cases showed no significant changes or deterioration. All 8
patients with blurred vision lost the symptom postopera-
tively. Among the 7 patients with hypomnesia, obvious
improvement was observed in 5 cases and no significant
improvement in the remaining 2. Among the 7 patients
with dysphasia, obvious improvement was observed in 4
cases, no changes in 2 cases, and deterioration in 1 case.
The one patient with facial palsy demonstrated no obvious
improvements after operation and finally lost to follow-up.
After the operation, new hemiparesis occurred was ob-
served in 8 cases. Transitory worsening of hemiparesis but
significant improvement within 2 weeks was observed in 6
Table 2 Image features of 33 adult UTGs
Characteristics No. (%) of patients
Location of tumors
Confined in the thalamus 9 (27.3)
Extension to the brainstem 12 (36.4) (including 4 extensions to
the basal ganglia or internal capsule
and 1 extension to the contralateral
thalamus)
Extension to the contralateral
thalamus
3 (9.1) (including 1 extension to the
brainstem and 1 extension to the
internal capsule)
Extension to the basal ganglia
and/or internal capsule
14 (42.4) (including 4 extensions to
the brainstem, 1 extension to the
contralateral thalamus, and 1









Hypointense T1 and mixed T2 2 (6.1)
Mixed T1 and hyperintense T2 11 (33.3)




Table 3 Treatment details of 33 adult UTGs
Characteristics No. (%) of patients
Approaches
Parieto-occipital transventriclular approach 22(66.7)




Extent of surgical resection
Gross total tumor resection (≥90 %) 19 (57.6)
Subtotal tumor resection (≥80 but <90 %) 9 (27.3)
Partial tumor resection (<80 %) 5 (15.2)
Location of residual tumor
Posterior part of the third ventricle 3 (20)a
Lateral part of the thalamus adjacent to the
internal capsule
6 (40)a
Medial and internal part of the thalamus 6 (40)a
Preoperative ventricular peritoneal shunt
Yes 7 (21.2)
No 26 (78.8)




Radiotherapy + chemotherapy 10 (30.3)
Radiotherapy 16 (48.5)
Chemotherapy 2 (6.1)
aPercentage refers to the comparison reasons of the total residual tumor
numbers of the patients (100 %)
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cases; no obvious improvement was observed in the other 2
cases at the last follow-up. New dysphasia was observed in
3 cases, with transitory worsening and spontaneously re-
gression within 3 months in all 3 cases. No new occurrence
of hyperesthesia was observed in this series. No patient had
seizures requiring additional antiepileptic medication pre-
or postoperatively.
Recurrence and survival among patients with UTGs at
follow-up
The follow-up period ranged from 1 week to 49 months;
the median follow-up time was 17 months. At the last
follow-up, 21 patients had experienced tumor progression.
The median PFS was not available. The 1-year and 2-year
PFS rates were 51.5 and 9.1 %, respectively. Twenty-one
patients died of recurrent tumors, and the median OS was
not available. The 1-year and 2-year OS rates were 72.7
and 24.2 %, respectively. Kaplan-Meier plots of PFS and
OS are shown in Fig. 1.
Pathological features of UTGs
Pathological data are summarized in Table 1. Molecular
pathology results were available in 15 of the 33 UTGs.
Immunohistochemistrywas positive for P53 in 69.2 % of the
cases (9/13), Ki-67 in 90.9 % (10/11), GFAP in 90.9 % (10/
11), MGMT in 60 % (6/10), VEGF in 60 % (6/10), TOPO-II
in 80 % (8/10), P-170 in 50 % (5/10), MMP-9 in 90 % (9/
10), GST-π in 80 % (8/10), PTEN in 100 % (9/9), EGFR in
66.7 % (6/9), Oligo-2 in 100 % (9/9), etc. (Table 4).
Clinical, radiological, and pathological parameters
associated with PFS and OS
Parameters significantly associated with longer PFS and
OS were determined using the log-rank test and Cox
regression method (Table 5, Fig. 2, Additional files 1, 2, 3,
4, 5, 6, 7, and 8: Figures s1–s8). Univariate and multivari-
ate analysis revealed several factors were correlated with a
better PFS survival (Table 5). Also univariate and multi-
variate analysis revealed several factors were correlated
with a better PFS survival (Table 5). Cox regression ana-
lysis revealed that age <42 years, female sex, symptom
duration ≥2 months, cystic appearance, maximal tumor
diameter <3.9 cm, preoperative KPS ≥60, and gross total
resection were associated with a better PFS prognosis,
while left side (P = 0.259) and lower-pathological grade
(P = 0.531) failed to show statistical significance of a
better PFS survival. Cox regression analysis revealed
that age <42 years, female sex, left-sided tumor, symp-
tom duration ≥2 months, cystic appearance, maximal
tumor diameter <3.9 cm, lower-pathological grade, pre-
operative KPS ≥60, gross total resection, and postopera-
tive V-P shunt were also associated with a better OS
prognosis (Additional file 9: Tables S1 and S2).
Illustrative cases
Case 1
A lesion affecting the left thalamus and midbrain was
diagnosed radiologically in a 53-year-old male admit-
ted to our hospital. He reported having headache for
the past year and hypomnesia for the past 6 months.
Neurological examination revealed no obvious abnor-
mal findings. Radiological examination revealed a le-
sion located in the left thalamus and affecting the
midbrain with hypointense T1 and hyperintense T2
signals as well as partial heterogeneous enhancement
(Fig. 3). Thalamic glioma was diagnosed, and the pa-
tient underwent a subtotal resection of the tumor
using a parieto-occipital transventricular approach.
During surgery, the tumor appeared as a pinkish-gray
soft mass with a poorly defined border and a cystic
component of dark-yellow fluid in the posterior part
of the mass. The postoperative pathology diagnosis
was astrocytoma (WHO grade II). No immunohisto-
chemical staining was performed. The patient suffered
from a transient deterioration of the right limb motor
function and language nonfluency after surgery. After
2 weeks, his limb movements returned to normal and his
language fluency recovered. The patient was discharged
23 days after operation. Postoperative cranial radiotherapy
was performed. However, the tumor progressed after
19 months. The patient refused to undergo another sur-
gery, chemotherapy, or radiotherapy and died 25.5 months
after the operation.
Fig. 1 Kaplan-Meier plots of PFS and OS for 30 UTGs patients
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Case 33
A pathologic diagnosis of anaplastic astrocytoma with
transformation to glioblastoma was confirmed in a 48-
year-old male admitted to our hospital. He complained of
a motor dysfunction of his right lower limb for the past
2 weeks. Neurological examination revealed weakness of
his right lower limbs. The lesion showed mixed hypoin-
tense and isointense T1 and hyperintense T2 signals with
clear enhancement (Fig. 4). The patient underwent a gross
total resection using a parieto-occipital transventricular
approach. During the operation, the tumor was found to
be a gray-yellow soft mass with a poorly defined border.
The postoperative pathology report confirmed the diagno-
sis of anaplastic astrocytoma with transformation to
glioblastoma, which was immunopositive for MGMT,
PTEN, GFAP, Oligo-2, MMP-9, P53 and immunonegative
for EGFR, P-170, VEGF, TOPO-II, and GST-π. Limb
weakness partially improved over a span of 2 weeks, and
the patient was discharged 15 days after surgery. The
postoperative follow-up revealed tumor recurrence at
1.5 months after surgery. The patient underwent postop-
erative concurrent chemoradiotherapy (radiotherapy +
temozolomide) plus 10 cycles of temozolomide chemo-
therapy. The patient died 13 months after surgery.
Discussion
Several studies on thalamic glioma have been reported;
however, the patient outcomes have been poor regard-
less of the type of treatment, and no comprehensive
guidelines with regard to treatment are available [4–7,
11, 30]. Recent studies have demonstrated improved
survival of pediatric patients with thalamic glioma after
an aggressive tumor resection followed by postoperative
adjuvant therapy [15, 28, 29]. However, the prognosis of
thalamic glioma in adult patients after aggressive surgi-
cal treatment remains uncertain because adult thalamic
glioma cases have always been assessed together with
those of pediatric patients [3, 11, 18, 30–32], and no stud-
ies have been devoted solely to adult thalamic glioma.
Therefore, the present retrospective study was undertaken
to investigate the clinical features of unilateral thalamic
gliomas in adults as well as to analyze the parameters that
are likely to influence survival.
Basic clinical features correlated with prognosis
In the current series, several basic clinical features were
found to correlate with a better prognosis, namely, age
<42 years, symptom duration ≥2 months, and preoperative
KPS ≥60. Some of the results in our series are in accord-
ance with previously reported studies.
Age <42 years correlated with longer survival. This age of
onset result was consistent with those of previous studies
[1, 5, 33]. Moreover, previous studies also revealed better
outcome in thalamic tumor patients who were younger
than 40 years compared with older patients [5]. Similarly,
Nishio et al. also demonstrated that the outcome of youn-
ger patients was better than that of older patients despite
the same pathological diagnosis [4].
A symptom duration of ≥2 months was associated with
longer survival, a finding in agreement with a previous
study [15]. Moreover, in our study, we found that a short
duration of symptoms is often indicative of a high-grade
glioma (WHO grades III and IV). In the subgroup of
patients with symptom durations <2 months, the rate of
high-grade glioma was 100 % (compared with a rate of
46.7 % in patients with symptom durations ≥2 months)
(P = 0.002). This result is similar to the reports of
Cuccia [9].
A preoperative KPS ≥60 was correlated with longer
survival and may be an independent factor for better OS.
This result may reflect the fact that lower KPS may result
in a decreased ability of patients to withstand neurological
insults caused by the tumor, surgery, and/or adjuvant ther-
apies [34–36]. The median KPS of the current study was
Table 4 Molecular pathology features of 33 adult UTGs
Molecular pathologies UTGs no. (%) Molecular pathologies UTGs no.(%) Molecular pathologies UTGs no. (%)
P53 TOPO-II GST-π
+ 9(69.2) + 8(80) + 8(80)
− 4(30.7) − 2(20) − 2(20)
GFAP P-170 PTEN
+ 10(90.9) + 5(50) + 9(100)
− 1(9.1) − 5(50) − 0(0)
MGMT Oligo-2 EGFR
+ 6(60) + 9(100) + 6(66.7)
− 4(40) − 0(0) − 3(33.3)
VEGF MMP-9
+ 6(60) + 9(90)
− 4(40) − 1(10)
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Progression-free survival rates (%) P value Median
OS
(INR)a
Overall survival rates (%) P value
6 months 12 months 18 months 24 months 6 months 12 months 18 months 24 months
Age (years)
<42 N/A 87.5 62.5 25.0 6.3 <0.001 N/A 100.0 93.8 56.3 18.8 <0.001
≥42 N/A 64.3 50.0 28.6 14.3 N/A 71.4 64.3 35.7 35.7
Sex
Male N/A 78.9 47.4 31.6 10.5 0.037 N/A 94.7 84.2 57.9 36.8 <0.001
Female N/A 72.7 72.7 18.2 9.1 N/A 72.7 72.7 27.3 9.1
Lateral
Left N/A 84.6 69.2 30.8 15.4 <0.001 N/A 92.3 92.3 46.2 38.5 <0.001
Right N/A 70.6 47.1 23.5 5.9 N/A 82.4 70.6 47.1 17.6
Preoperative
kps
≥60 N/A 85.7 66.7 33.3 14.3 <0.001 N/A 95.2 90.5 52.3 23.8 <0.001
<60 9(3–20) 55.6 33.3 11.1 0.0 N/A 66.7 55.6 33.3 33.3
Postoperative
kps
≥60 N/A 84.0 72.0 36.0 16.0 <0.001 N/A 92.0 84.0 52.0 40.0 <0.001




≥2 N/A 93.3 73.3 40.0 20.0 <0.001 N/A 93.3 93.3 66.7 46.7 <0.001
<2 11(2–
24)
60.0 40.0 13.3 0.0 N/A 80.0 66.7 26.7 6.7
Cystic
changes
Yes N/A 85.7 71.4 42.9 28.6 <0.001 N/A 100.0 100.0 85.7 57.1 <0.001
No N/A 73.9 52.2 21.7 4.3 N/A 82.6 73.9 34.8 17.4
Diameter (cm)
<3.9 N/A 91.7 66.7 41.7 16.7 <0.001 N/A 91.7 91.7 50.0 33.3 <0.001
≥3.9 N/A 66.7 50.0 16.7 5.5 N/A 83.3 72.2 44.4 22.2
Pathology
Low grade N/A 100.0 100.0 50.0 25.0 <0.001 N/A 100.0 100.0 75.0 50.0 <0.001





100.0 75.0 25.0 0.0 – N/A 100.0 100.0 50.0 25.0 <0.001
No N/A 73.1 53.8 26.9 11.5 N/A 84.6 76.9 46.2 26.9
Resection
Gtr N/A 82.4 64.7 35.3 17.6 <0.001 N/A 88.2 76.5 52.9 35.3 <0.001
Str/pr 12
(2–20)
69.2 46.2 15.4 0.0 N/A 84.6 84.6 38.5 15.4
N/A not available
aMedian PFS and median OS was calculated based on the final status of follow-up
bMeans no correlation in univariate analysis
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Fig. 2 Patients with low-grade pathology have longer PFS (a) and OS (b) than patients with high-grade. Gross total tumor resection is significantly
associated with longer PFS (c) and OS (d)
Fig. 3 Case 1. Cranial MRI examination revealed unilateral thalamus glioma located in the left thalamus and midbrain with hypointense T1 (a) and
hyperintense T2 (b) signals, which were heterogeneously enhanced after injecting contrast agent (c–e). Postoperative MRI confirmed subtotal resection
(f–j). Pathological examination revealed a diagnosis of astrocytoma (WHO Grade II). Original magnification ×100
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60; a lower KPS score was observed in 9 cases (30 %),
which is substantially lower rate than previously reported
[6, 37]. The result of this study indicates that performance
of thalamic patients was substantially worse on admission
than for patients with glioma in other parts of the brain,
which points to a higher surgical risk when performing a
tumor resection in these patients. Of note, the 3 (pre-
operative KPS categories 40, 50, and 60, respectively) de-
veloped within 2 weeks after surgery in this group of
patients.
Tumor biological features correlated with prognosis
Tumors with cystic appearance were correlated with
longer survival. The rate of cystic appearance in our
study was 24.2 %, which is similar to the rate of 11.5–
53 % in previous studies [13, 15, 38]. All cystic compo-
nents as well as the walls of the cysts were completely
excised during surgery. This approach is in accordance
with Moshel’s study because cystic thalamic tumors also
contain tumor cells in the cyst wall [38]. The pathology
of tumors with cystic appearance in our study included
astrocytoma in 4 cases, oligodendroastrocytoma in 1
case, anaplastic astrocytoma in 1 case, anaplastic oligo-
dendroastrocytoma in 1 case, and glioblastoma in 1 case.
No thalamus pilocytic astrocyomas were present in our
study; this result is notably different from the thalamic
tumors observed in children [15, 39].
A maximal tumor diameter of <3.9 cm correlated with
longer survival. Few studies have indicated a correlation
between tumor diameter and survival [11, 16]. Although,
a previous study on pediatric thalamic glioma, Kramm
failed to show a significant correlation between tumor
diameter and survival [16], larger tumors may present
more challenges to surgeons [38].
Low-grade pathology was correlated with longer sur-
vival and was also an independent factor for better OS.
Tumor pathology has been generally accepted as key
factor influencing survival [8, 28, 33]. Modern neuroim-
aging methods have contributed to a better understand-
ing of the patterns of tumor growth. Thalamic gliomas
are thought to grow along three primary pathways: along
the white matter, underneath the ventricular ependyma,
and through the cerebralspinal fluid pathways [8, 40].
Subsequently, surrounding tissues, such as the internal
capsule, the basal ganglia, the mesencephalic tegmen-
tum, and the hypothalamic structures (and their corre-
sponding functions), may be affected [22, 41]. From this
point of view, patients with glioma of higher pathology
grade may be more strongly affected by the malignancy
features and face a higher risk during surgery and other
comprehensive treatments.
Clinical treatment correlated with prognosis
CSF has long been a problem in thalamic glioma pa-
tients. Thalamic gliomas are apt to cause obstruction of
the third or lateral ventricles. V-P shunt is one of the
most accepted procedures for maintaining CSF circula-
tion. Baroncini discussed CSF obstruction in pediatric
thalamic glioma patients [28]; however, the correlation
between V-P shunt and patient survival has never been
examined. In the present study, we analyzed the correl-
ation between survival and V-P shunt due to periopera-
tive acute hydrocephalus. We found that postoperative
V-P shunt correlated with longer OS. The infiltrative
nature and the growth pattern of thalamic glioma likely
contribute to the worsening of patients’ clinical status
[40]. Based on these results, we also hypothesize that the
occlusion of CSF circulation may be another main con-
tributor to the poor prognosis because ventriculomagely
and/or hydrocephalus were present in nearly all reported
series.
Fig. 4 Case 33. Cranial MRI examination revealed unilateral thalamus glioma located in the right thalamus and midbrain with mixed hypointense
and hyperintense (a) and hyperintense T2 (b) signals with clear enhancement (c–e). Postoperative MRI confirmed subtotal resection (f–j). Original
magnification ×100
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Gross total tumor resection correlated with longer sur-
vival. Thalamic gliomas have long been a challenge and are
considered difficult to excise. Most of these tumors received
only partial resection, biopsy, or only radiotherapy for
palliative care in earlier studies. However, with the advance-
ment of microsurgical techniques, recent studies have
reported improved survival following aggressive tumor re-
section in pediatric thalamic glioma patients [15, 28, 29],
which indicates that current cases of thalamic glioma can
be resected with acceptable complications nowadays. The
present study, focused exclusively on adult UTG patients,
found a statistically significant correlation between gross
total tumor resection and survival. Therefore, more aggres-
sive cytoreductive treatments should also be considered for
these tumors.
Study limitations
This retrospective study was based on a small series of
cases. Consequently, our conclusions were based on the
statistical analysis of a small number of patients and
should be interpreted with caution.
Conclusions
Unilateral thalamic glioma in adults represents a distinct
clinical subtype of thalamic gliomas. Tumors with specific
features, such as cystic appearances in radiology, may
indicate better prognosis. Moreover, using perioperative
ultrasound techniques and improved surgical techniques,
maximal safe resection was often feasible and provided
prognostic benefits with UTGs. However, the more funda-
mental biological features and the recommendation of
maximal safe resection for UTGs whenever possible to pro-
mote prolonged survival still need to be further investigated
in larger series.
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